Loading clinical trials...

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer | Clinical Trials | Clareo Health

WITHDRAWNPHASE1

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Pilot Study of 89Zr Panitumumab in Pancreas Cancer

NCT04833959•Stanford University

Summary

The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Confirmed diagnosis of pancreatic cancer.

Exclusion Criteria

•Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.
•History of infusion reactions to monoclonal antibody therapies.
•Pregnant or breastfeeding.
•Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
•Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
•Severe renal disease or anuria.
•Known hypersensitivity to deferoxamine or any of its components.

Locations (1)

Stanford University

Stanford, California, United States

Key Dates

Start Date

March 26, 2021

Primary Completion Date

March 1, 2024

Completion Date

March 1, 2024

Last Updated

June 21, 2024

Conditions

Pancreas Cancer

Interventions

89Zr-panitumumab

DRUG

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

NCT04485286

Lung CancerRadiation Fibrosis+2 more

View study

RECRUITINGPHASE1/PHASE2

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

NCT04605913

Pancreas CancerMetastatic Pancreatic Cancer+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 21, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Inclusion Criteria

Exclusion Criteria

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

A Study of MGC026 in Participants With Advanced Solid Tumors

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors